Stock Market Live June 9, 2026: S&P 500 (SPY) Bouncing Back with Tech

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Chris Lange | Dec 10, 2014 at 10:00 AM EST

Are Investors Signaling Optimism in Biotechs Through Short Interest?

The short interest data are out for the November 28 settlement date, and 24/7 Wall St. has reviewed the top…

Douglas A. McIntyre | Dec 10, 2014 at 6:30 AM EST

Norway’s Oil Decline Accelerating

New oil projects are being scrapped in Norway amid falling production and low oil prices.

Chris Lange | Dec 9, 2014 at 11:35 AM EST

Bellicum Sets Pricing Terms for IPO

Bellicum Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering.

Lee Jackson | Dec 9, 2014 at 8:50 AM EST

After Big Cubist Buy, Are These 2 Stocks Next to Be Acquired?

SunTrust Robinson Humphrey analysts say in a research note that Achaogen and Cempra could be in play as acquisition targets.

Paul Ausick | Dec 8, 2014 at 8:20 AM EST

Merck, Cubist Agree to $9.5 Billion Acquisition

Merck will acquire Cubist for $102 a share, or, about $9.5 billion, including $1.1 billion in Cubist’s net debt and…

Jon C. Ogg | Dec 4, 2014 at 12:10 PM EST

MannKind Sees More Insider Selling

MannKind saw its shares trading lower on Thursday. The culprit may simply be insiders selling more shares.

Chris Lange | Dec 4, 2014 at 10:35 AM EST

Array BioPharma: When Losing a Partnership Is Good News

Array BioPharma has announced that it had reached a definitive agreement with Novartis to regain full worldwide rights to cancer…

Chris Lange | Dec 4, 2014 at 9:40 AM EST

Credit Suisse Sees 2 Biotech Stocks That Could Double in 2015

Credit Suisse has released a biotech research report that has their top picks for upside potential in the biotech segment…

Chris Lange | Dec 2, 2014 at 9:15 AM EST

Are Avanir Shareholders Getting Enough in the Buyout?

Avanir Pharmaceuticals announced that it has entered into a definitive agreement with Otsuka Pharmaceutical for a $17.00 per share buyout.

Jon C. Ogg | Dec 1, 2014 at 2:10 PM EST

5 Critical Biotech Drug Dates and Events for December

At least five upcoming dates could be big days in December, for better or worse, for individual biotech stocks.

Paul Ausick | Nov 30, 2014 at 8:25 AM EST

Regenerative Medicine Company on Track for IPO This Week

The week after the Thanksgiving holiday stacks up to be another quiet one on the IPO front.

Chris Lange | Nov 26, 2014 at 11:07 AM EST

Mixed Readings For Biotech Short Interest

ThinkstockThe short interest data are out for the November 14 settlement date. Biotech companies are considered a riskier group of…

Chris Lange | Nov 24, 2014 at 10:23 AM EST

Amgen Surprise, Discontinues Stomach Cancer Drug Study

ThinkstockAmgen Inc. (NASDAQ: AMGN) announced the termination of all Amgen-sponsored clinical studies of rilotumumab in advanced gastric cancer. This includes…

Chris Lange | Nov 24, 2014 at 9:15 AM EST

Big News for Ebola Stocks

Monday may have started out as a fairly quiet news day for most stock sectors on a shortened week, but…

Jon C. Ogg | Nov 21, 2014 at 10:20 AM EST

5 Health Care Stocks That Need to Play Serious Catch Up

24/7 Wall St. has identified five of the lowest performing health care stocks over the past month which need to…

1 … 274 275 276 277 278 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Are Investors Signaling Optimism in Biotechs Through Short Interest?

Norway’s Oil Decline Accelerating

Bellicum Sets Pricing Terms for IPO

After Big Cubist Buy, Are These 2 Stocks Next to Be Acquired?

Merck, Cubist Agree to $9.5 Billion Acquisition

MannKind Sees More Insider Selling

Array BioPharma: When Losing a Partnership Is Good News

Credit Suisse Sees 2 Biotech Stocks That Could Double in 2015

Are Avanir Shareholders Getting Enough in the Buyout?

5 Critical Biotech Drug Dates and Events for December

Regenerative Medicine Company on Track for IPO This Week

Mixed Readings For Biotech Short Interest

Amgen Surprise, Discontinues Stomach Cancer Drug Study

Big News for Ebola Stocks

5 Health Care Stocks That Need to Play Serious Catch Up

Stock Market Live June 9, 2026: S&P 500 (SPY) Bouncing Back with Tech

Live Nasdaq Composite: AI Stocks Reclaim Lost Ground as Volatility Eases and Oil Pulls Back

One Factory to Rule Them All: How Musk’s Terafab Could Rewrite the Scale of U.S. Chip Production

IBM Just Placed a $10 Billion Bet to Become the Nvidia of Quantum Computing

Microsoft’s $9K Return on $1K Crushes The Market

Comfortable Off-Grid Living Costs More Than Most People Think. A Lot More.

I'm 65 and Widowed. Switching My Social Security Out of Fear Could Shrink My Check 8% a Year for Life

One Factory to Rule Them All: How Musk’s Terafab Could Rewrite the Scale of U.S. Chip Production

IBM Just Placed a $10 Billion Bet to Become the Nvidia of Quantum Computing

Health and Healthcare Articles

All Health and Healthcare Articles

Are Investors Signaling Optimism in Biotechs Through Short Interest?

Norway’s Oil Decline Accelerating

Bellicum Sets Pricing Terms for IPO

After Big Cubist Buy, Are These 2 Stocks Next to Be Acquired?

Merck, Cubist Agree to $9.5 Billion Acquisition

MannKind Sees More Insider Selling

Array BioPharma: When Losing a Partnership Is Good News

Credit Suisse Sees 2 Biotech Stocks That Could Double in 2015

Are Avanir Shareholders Getting Enough in the Buyout?

5 Critical Biotech Drug Dates and Events for December

Regenerative Medicine Company on Track for IPO This Week

Mixed Readings For Biotech Short Interest

Amgen Surprise, Discontinues Stomach Cancer Drug Study

Big News for Ebola Stocks

5 Health Care Stocks That Need to Play Serious Catch Up

Stock Market Live June 9, 2026: S&P 500 (SPY) Bouncing Back with Tech

Live Nasdaq Composite: AI Stocks Reclaim Lost Ground as Volatility Eases and Oil Pulls Back

One Factory to Rule Them All: How Musk’s Terafab Could Rewrite the Scale of U.S. Chip Production

IBM Just Placed a $10 Billion Bet to Become the Nvidia of Quantum Computing

Microsoft’s $9K Return on $1K Crushes The Market

Featured Reads

Comfortable Off-Grid Living Costs More Than Most People Think. A Lot More.

I'm 65 and Widowed. Switching My Social Security Out of Fear Could Shrink My Check 8% a Year for Life